ACUVUE THERAVISION WITH KETOTIFEN

Peak

ketotifen fumarate

NDAOPHTHALMICDRUG-ELUTING CONTACT LENS
Approved
Feb 2022
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
4

Mechanism of Action

state, the lens when placed on the cornea, acts as a refracting medium to focus light rays on the retina to correct refractive ametropia for as long as the lens is worn (up to 24 hours while awake). Drug Component Ketotifen fumarate, a benzocycloheptathiophene derivative, is a H 1 receptor…

Clinical Trials (4)

NCT05815758Phase 3Completed

Evaluation of the Safety and Pharmacokinetics of Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution

Started Apr 2023
512 enrolled
Allergic Conjunctivitis
NCT05591755Phase 3Completed

Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination in Adults With Seasonal Allergic Conjunctivitis

Started Nov 2022
229 enrolled
Seasonal Allergic Conjunctivitis
NCT05579730Phase 3Completed

Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination for the Treatment of Allergic Conjunctivitis

Started Oct 2022
188 enrolled
Allergic Conjunctivitis
NCT03489941Phase 3Completed

A Single-Center Evaluation of the Relative Efficacy of EM-100 Compared to Zaditor® (Ketotifen Fumarate Ophthalmic Solution 0.035%) and Vehicle

Started Apr 2018
65 enrolled
Allergic Conjunctivitis

Loss of Exclusivity

LOE Date
Jun 27, 2030
52 months away
Patent Expiry
Jun 27, 2030

Patent Records (2)

Patent #ExpiryTypeUse Code
9474746
Mar 27, 2028
Product
9962376
Jun 27, 2030
Product